Inicio>>Signaling Pathways>> DNA Damage/DNA Repair>> DNA Methyltransferase>>CM-579 trihydrochloride

CM-579 trihydrochloride

Catalog No.GC35714

El trihidrocloruro de CM-579 es el primer inhibidor dual reversible de su clase de G9a y DNMT, con valores IC50 de 16 nM, 32 nM para G9a y DNMT, respectivamente. Tiene una potente actividad celular in vitro en una amplia gama de células cancerosas.

Products are for research use only. Not for human use. We do not sell to patients.

CM-579 trihydrochloride Chemical Structure

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
307,00 $
Disponible
5mg
232,00 $
Disponible
10mg
362,00 $
Disponible
50mg
1.020,00 $
Disponible
100mg
1.391,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

CM-579 trihydrochloride is a first-in-class reversible, dual inhibitor of G9a and DNMT, with IC50 values of 16 nM, 32 nM for G9a and DNMT, respectively. Has potent in vitro cellular activity in a wide range of cancer cells[1]. DNA Methyltransferase|32 nM (IC50)|DNMT1|1.5 nM (Kd)|DNMT3A|92 nM (IC50)|DNMT3B|1000 nM (IC50)|G9a|16 nM (IC50)

The Kd of CM-579 for DNMT1 is 1.5 nM, CM-579 also inhibits DNMT3A and DNMT3B, with IC50s of 92 nM and 1000 nM, respectively[1].

[1]. San JosÉ-EnÉriz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.

Reseñas

Review for CM-579 trihydrochloride

Average Rating: 5 ★★★★★ (Based on Reviews and 34 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for CM-579 trihydrochloride

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.